NCT06891716View on ClinicalTrials.gov

[18F]ACI-19626 PET in TDP-43 Proteinopathies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Frontotemporal Dementia (FTD)Amyotrophic Lateral Sclerosis (ALS)TDP-43 ProteinopathiesSuspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)Alzheimer's Disease (AD)
Interventions
OTHER

[18F]ACI-19626

\[18F\]ACI-19626 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of TDP-43 deposits.

Trial Locations (1)

Unknown

RECRUITING

Amsterdam UMC, Amsterdam

Sponsors

Lead Sponsor

AC Immune SA
All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

lead

AC Immune SA

INDUSTRY